Treatment considerations for the management of fibrodysplasia ossificans progressiva

被引：38

作者：

Glaser D.L. ^{[1
,3
]}

Kaplan F.S. ^{[1
,2
,3
,4
]}

机构：

[1] Department of Orthopaedic Surgery, University of Pennsylvania, School of Medicine, Philadelphia, PA

[2] Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA

[3] Center for Research in FOP and Related Disorders, University of Pennsylvania, School of Medicine, Philadelphia, PA

[4] Department of Orthopaedic Surgery, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, Silverstein Two

来源：

Clinical Reviews in Bone and Mineral Metabolism | 2005年 / 3卷 / 3-4期

关键词：

Fibrodysplasia ossificans progressiva (FOP); Pathophysiology; Treatment guidelines;

D O I：

10.1385/BMM:3:3-4:243

中图分类号：

学科分类号：

摘要：

The ultimate goal of research on fibrodysplasia ossificans progressiva (FOP) is the development of treatments that will prevent, halt, or even reverse the progression of the condition. Despite advances in understanding the pathophysiology of FOP, there are no therapies with scientifically proven benefits for the prevention or treatment of FOP. Insights obtained from the research laboratory and from the treatment of hundreds of patients worldwide have allowed us to identify targets for potential therapies. Some of these therapies involve the use of currently available medications, whereas others involve novel therapeutic approaches that are in preclinical testing. In this article, we will review the scientific basis for considering various therapeutic options based on the known pathophysiology of FOP. Because there are presently no proven preventions or treatments for the condition, this article is intended to represent an opinion of the authors that may be helpful to others who face similar situations. © Copyright 2005 by Humana Press Inc. All rights of any nature whatsoever reserved.

引用

页码：243 / 250

页数：7

共 51 条

[31]

Emerson S.G., Kaplan F.S., Marrow stem cell transplantation in fibrodysplasia ossificans progressiva, Clin Orthop, 392, pp. 451-455, (2001)

[32]

Kaplan F.S., Glaser D.L., Shore E.M., Emerson S.G., Bone marrow transplantation in a patient with fibrodysplasia ossificans progressiva, Clin Orthop, 422, (2004)

[33]

Shafritz A.B., Shore E.M., Gannon F.H., Et al., Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva (FOP), N Engl J Med, 335, pp. 555-561, (1996)

[34]

Kitterman J.A., Kantanie S., Rocke D.M., Kaplan F.S., Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva, Pediatrics, (2005)

[35]

Kussmaul W.G., Esmail A.N., Sagar Y., Ross J., Gregory S., Kaplan F.S., Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva, Clin Orthop, 346, pp. 104-109, (1998)

[36]

Kaplan F.S., Sawyer J., Connors S., Et al., Urinary basic fibroblast growth factor: A biochemical marker for preosseous fibroproliferative lesions in patients with FOP, Clin Orthop, 346, pp. 59-65, (1998)

[37]

Kaplan F.S., Tabas J., Gannon F.H., Finkel G., Hahn G.V., Zasloff M.A., The histopathology of fibrodysplasia ossificans progressiva: An endochondral process, J Bone Joint Surg Am, 75 A, pp. 220-230, (1993)

[38]

Langenfeld E.M., Langenfeld J., Bone morphogenetic protein-2 simulates angiogenesis in developing tumors, Mol Cancer Res, 2, 3, pp. 141-149, (2004)

[39]

Huang J., Frischer J.S., Serur A., Et al., Regression of established tumors and metastases by potent vascular endothelial grown factor blockade, Proc Natl Acad Sci, 100, pp. 7785-7790, (2003)

[40]

Stephens T., Brynner R., Dark Remedy: The Impact of Thalidomide and Its Revival As a Vital Medicine, (2001)

← 1 2 3 4 5 6 →